Meeting
2014 ASCO Annual Meeting
Safety and immunologic efficacy of personalized multiple HLA class I-restricted peptide vaccines for breast cancer patients in the adjuvant setting.
Authors
Uhi Toh
Department of Surgery, Kurume University Faculty of Medicine, Kurume, Japan
Uhi Toh , Nobutaka Iwakuma , Mai Mishima , Miki Takenaka , Ryuji Takahashi , Mina Furukawa , Teruhiko Fujii , Etsuyo Ogo , Shino Nakagawa , Maki Tanaka , Tetsuro Sasada , Kyogo Itoh , Yoshito Akagi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Immunotherapy
Track
Developmental Therapeutics
Sub Track
Vaccines
Clinical Trial Registration Number
000003081
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS3130)
DOI
10.1200/jco.2014.32.15_suppl.tps3130
Abstract #
TPS3130
Poster Bd #
187B
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Efficacy finding cohort of a cancer peptide vaccine, TAS0313, in treating recurrent glioblastoma.
First Author: Yoshiki Arakawa
Poster
2022 ASCO Annual Meeting
EO2401, a novel microbiome-derived therapeutic vaccine for patients with adrenocortical carcinoma (ACC): Preliminary results of the SPENCER study.
First Author: Eric Baudin
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Immunologic efficacy of E39 & E39' vaccination in a phase I/IIa trial in ovarian and endometrial cancer patients.
First Author: Tommy A Brown
Poster
2013 ASCO Annual Meeting
Safety and efficacy of the HER2-derived GP2 peptide vaccine in combination with trastuzumab for breast cancer patients in the adjuvant setting.
First Author: Ritesh Patil